A reasonably likely surrogate endpoint for metabolic dysfunction–associated steatohepatitis
Year: 2026
Type: article
Source: Nature Medicine
Authors: Arun J. Sanyal, Michelle T. Long, Nancy Obuchowski, Roberto A. Calle, Raj Vuppalanchi, Brent Neuschwander-Tetri, Rohit Loomba, Katherine Yates, Patricia Grebenstein, Melissa A. Jones, Tania N. Kamphaus, on behalf of the Surrogate Endpoints Workstream of the FNIH, Tre LaRosa, Vian Azzu, Jonathan G. Stine, Belle Vivica van Rosmalen, Mathieu Petitjean, Mary Erickson, Alina Allen, Rebecca Taub, Suneil Hosmane, Tony Villiotti, Mark L. Hartman, Daria B. Crittenden, Céline Fournier-Poizat, Daniel Dugger, Thomas Norton, William Esler, Ben Da, Hank Mansbach, Theresa Perney
Institutions: Virginia Commonwealth University, Virginia Commonwealth University Medical Center, Novo Nordisk (Denmark), Cleveland Clinic, New York Medical College, Regeneron (United States), Indiana University School of Medicine, Saint Louis University, University of California San Diego, Johns Hopkins University, Foundation for the National Institutes of Health, AstraZeneca (United Kingdom), AstraZeneca (United States), Eli Lilly (United States), Intercept Pharmaceuticals (United States), Mayo Clinic, Madrigal Pharmaceuticals (United States), Echosens (France), Genentech, Pfizer (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), 89bio (United States)
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7156674604